PBAC's latest decision on Rabeprazole: Recommended (2022). Considered for Gastro-oesophageal reflux disease (GORD), prevention of relapse of GORD, symptomatic treatment of GORD, and treatment of active duodenal or gastric ulcer.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2022
Submissions
1
2022 → 2022
Eligible population
Patients requiring short-term treatment courses of rabeprazole 20 mg for GORD or ulcer disease (4-8 weeks).
Therapy area
Gastroenterology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
rabeprazole 20 mg 30-tablet pack
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated as no new clinical evidence or efficacy improvement claimed.